Pricing Log in Create free account

Immunocore Holdings PLC Sponsored ADR (IMCR) vs Ocular Therapeutix, Inc. (OCUL)

Immunocore Holdings PLC Sponsored ADR and Ocular Therapeutix, Inc. are both Biotechnology companies. Immunocore Holdings PLC Sponsored ADR and Ocular Therapeutix, Inc. are of similar size ($1.5B and $1.4B). Immunocore Holdings PLC Sponsored ADR grew revenue faster over the last twelve months: 13.1% against −8.14%. Immunocore Holdings PLC Sponsored ADR has the higher net margin (−7.48% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Immunocore Holdings PLC Sponsored ADR leads on 13 and Ocular Therapeutix, Inc. on 4.

Valuation

Metric IMCR OCUL Biotechnology median
P/E n/m n/m 10.60
P/S 3.71 28.61 9.40
P/B 3.80 2.86 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 2.64 18.51 9.02
Earnings yield (2.06%) (21.45%) (32.88%)
Free cash flow yield (1.14%) (17.13%) (23.13%)

Profitability

Metric IMCR OCUL Biotechnology median
Gross margin 98.86% 87.11% 68.51%
Operating margin (6.76%) (603.04%) 0.00%
Net margin (7.48%) (579.10%) 0.00%
Free cash flow margin (4.24%) (490.07%) 0.00%
Return on equity (7.87%) (72.99%) (51.96%)
Return on assets (2.88%) (53.70%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMCR OCUL Biotechnology median
Revenue growth (TTM) 13.10% (8.14%) 6.76%
EPS growth (last fiscal year) 30.39% (16.39%) 29.88%
Revenue growth, 5-year CAGR 59.57% 24.45% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCR OCUL Biotechnology median
Debt to equity 0.94 0.14 0.00
Current ratio 4.62 13.11 4.97
Net debt to EBITDA 11.19 2.51 1.01

Dividend

Metric IMCR OCUL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMCR OCUL Biotechnology median
Market cap 1.46b 1.41b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack